• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液透析患者膳食磷和钙的吸收

The absorption of dietary phosphorus and calcium in hemodialysis patients.

作者信息

Ramirez J A, Emmett M, White M G, Fathi N, Santa Ana C A, Morawski S G, Fordtran J S

出版信息

Kidney Int. 1986 Nov;30(5):753-9. doi: 10.1038/ki.1986.252.

DOI:10.1038/ki.1986.252
PMID:3784305
Abstract

Absorption of dietary phosphorus plays a critical role in the development of metabolic bone diseases in patients with chronic renal failure. However, phosphorus absorption is difficult to quantitate in dialysis patients because the dialysis treatments complicate metabolic balance studies. Utilizing a recently developed technique which permits measurement of net absorption of dietary constituents after a single meal, we measured phosphorus absorption in dialysis patients. The following observations were made: A.) Following a meal containing approximately 300 mg phosphorus, mean phosphorus absorption in five hemodialysis patients (with severe vitamin D deficiency) was only slightly less than in matched controls (186 +/- 35 vs. 242 +/- 30). B.) After dialysis patients were treated with 1,25(OH)2-D3, phosphorus absorption increased from 186 +/- 35 to 272 +/- 16 mg (P less than 0.025). C.) The effect of three aluminum containing antacids on phosphorus absorption was studied; each slightly reduced the absorption of phosphorus compared to placebo (P less than 0.01), but there was no significant difference between them. D.) Aluminum hydroxide and calcium carbonate each reduced dietary phosphorus absorption to approximately the same extent. Calcium carbonate ingestion was associated with sharply increased calcium absorption. The absorption of dietary phosphorus is influenced only modestly by 1,25(OH)2-D3 and is inhibited to an equal but only modest degree by various aluminum antacids and by calcium carbonate.

摘要

膳食磷的吸收在慢性肾衰竭患者代谢性骨病的发展中起着关键作用。然而,由于透析治疗使代谢平衡研究变得复杂,因此在透析患者中难以对磷的吸收进行定量。利用一种最近开发的技术,该技术允许在单次进食后测量膳食成分的净吸收,我们测量了透析患者的磷吸收。得出以下观察结果:A. 进食含约300毫克磷的一餐之后,五名血液透析患者(严重维生素D缺乏)的平均磷吸收仅略低于匹配的对照组(186±35对242±30)。B. 透析患者接受1,25(OH)₂-D₃治疗后,磷吸收从186±35增加到272±16毫克(P<0.025)。C. 研究了三种含铝抗酸剂对磷吸收的影响;与安慰剂相比,每种抗酸剂均使磷吸收略有降低(P<0.01),但它们之间无显著差异。D. 氢氧化铝和碳酸钙对膳食磷吸收的降低程度大致相同。摄入碳酸钙与钙吸收急剧增加有关。膳食磷的吸收仅受到1,25(OH)₂-D₃的适度影响,并受到各种铝抗酸剂和碳酸钙同等但仅适度程度的抑制。

相似文献

1
The absorption of dietary phosphorus and calcium in hemodialysis patients.血液透析患者膳食磷和钙的吸收
Kidney Int. 1986 Nov;30(5):753-9. doi: 10.1038/ki.1986.252.
2
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
3
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].3、4、5期慢性肾脏病(未透析)患者矿物质代谢的变化
Nefrologia. 2008;28 Suppl 3:67-78.
4
Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.
Am J Kidney Dis. 1988 Apr;11(4):338-42. doi: 10.1016/s0272-6386(88)80140-9.
5
Effect of small doses of aluminum-containing antacids on calcium and phosphorus metabolism.小剂量含铝抗酸剂对钙和磷代谢的影响。
Am J Clin Nutr. 1982 Jul;36(1):32-40. doi: 10.1093/ajcn/36.1.32.
6
Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.患有慢性肾病的儿童和年轻人在接受氢氧化铝治疗及透析过程中的铝蓄积。
N Engl J Med. 1991 Feb 21;324(8):527-31. doi: 10.1056/NEJM199102213240804.
7
The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances, the serum parathyroid hormone concentration and the aluminium content of bone in patients with chronic renal failure.
Clin Sci. 1972 Oct;43(4):519-31. doi: 10.1042/cs0430519.
8
Calcium acetate, an effective phosphorus binder in patients with renal failure.
Kidney Int. 1989 Oct;36(4):690-5. doi: 10.1038/ki.1989.247.
9
[Effect of aluminium-hydroxide-containing antacids on the intestinal absorption of iron in patients on long-term dialysis].
Schweiz Med Wochenschr. 1977 Jul 30;107(30):1064-6.
10
Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoneal dialysis compared with hemodialysis.透析患者肾性骨营养不良的对照研究。与血液透析相比,持续非卧床腹膜透析的反应更佳。
Am J Med. 1987 Jun;82(6):1148-56. doi: 10.1016/0002-9343(87)90217-8.

引用本文的文献

1
Intradialytic serum phosphate variations are associated with low PTH levels.透析过程中血清磷酸盐的变化与低 PTH 水平有关。
J Nephrol. 2024 Sep;37(7):1911-1919. doi: 10.1007/s40620-024-02062-y. Epub 2024 Aug 23.
2
Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study.碳酸司维拉姆在中国非透析慢性肾脏病高磷血症患者中的疗效与安全性:一项随机、双盲、平行组研究。
Kidney Dis (Basel). 2022 Dec 15;9(2):82-93. doi: 10.1159/000527833. eCollection 2023 Apr.
3
Effects of pharmacological inhibition of the sodium-dependent phosphate cotransporter 2b (NPT2b) on intestinal phosphate absorption in mouse and rat models.
药物抑制钠依赖性磷酸盐协同转运蛋白 2b(NPT2b)对小鼠和大鼠模型肠道磷酸盐吸收的影响。
Pharmacol Res Perspect. 2022 Apr;10(2):e00938. doi: 10.1002/prp2.938.
4
Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia.高磷血症管理中当前方法及临床差距的多学科视角
Int J Nephrol Renovasc Dis. 2021 Aug 6;14:301-311. doi: 10.2147/IJNRD.S318593. eCollection 2021.
5
Phosphate Balance and CKD-Mineral Bone Disease.磷平衡与慢性肾脏病-矿物质和骨异常
Kidney Int Rep. 2021 May 17;6(8):2049-2058. doi: 10.1016/j.ekir.2021.05.012. eCollection 2021 Aug.
6
Development of a quantitative systems pharmacology model of chronic kidney disease: metabolic bone disorder.慢性肾脏病-代谢性骨病的定量系统药理学模型的建立。
Am J Physiol Renal Physiol. 2021 Feb 1;320(2):F203-F211. doi: 10.1152/ajprenal.00159.2020. Epub 2020 Dec 14.
7
Strategies for Phosphate Control in Patients With CKD.慢性肾脏病患者磷酸盐控制策略
Kidney Int Rep. 2019 Jun 20;4(8):1043-1056. doi: 10.1016/j.ekir.2019.06.002. eCollection 2019 Aug.
8
Interventional study to improve adherence to phosphate binder treatment in dialysis patients.改善透析患者对磷结合剂治疗依从性的干预性研究。
BMC Nephrol. 2019 May 17;20(1):178. doi: 10.1186/s12882-019-1334-x.
9
The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease.磷结合药物和低膳食磷蛋白比值在降低慢性肾脏病患者肠道磷负荷中的作用。
Nutr Diabetes. 2019 Apr 3;9(1):14. doi: 10.1038/s41387-019-0080-2.
10
The Bone-Vasculature Axis: Calcium Supplementation and the Role of Vitamin K.骨-血管轴:补钙与维生素K的作用
Front Cardiovasc Med. 2019 Feb 5;6:6. doi: 10.3389/fcvm.2019.00006. eCollection 2019.